Genmab announced that Johnson & Johnson reported worldwide net trade sales of DARZALEX® (daratumumab) totaling USD 14,351 million in 2025. The U.S. market accounted for USD 8,266 million of these sales, while the rest of the world contributed USD 6,085 million. This performance reflects continued strong demand for both the intravenous formulation and the subcutaneous DARZALEX FASPRO® product, which includes hyaluronidase-fihj to facilitate at-home administration.

Under its license agreement with J&J, Genmab receives tiered royalties on all global net sales of DARZALEX, covering both intravenous and subcutaneous formats. Based on the reported USD 14.35 billion in net sales, Genmab’s royalty revenue is estimated to represent a material contribution to its annual top line, bolstering cash flow and supporting continued investment in late-stage clinical programs.

DARZALEX FASPRO® subcutaneous injections accounted for an increasing proportion of total sales in 2025, as more treatment centers and home-care providers adopted the shorter administration time and reduced infusion-related reaction profile. Industry data indicate that SC dosing now represents approximately 40% of total DARZALEX units, a shift that underpins higher patient throughput and may improve long-term market share against competing multiple myeloma therapies.

The robust royalty inflows from DARZALEX provide Genmab with additional financial flexibility to advance its proprietary pipeline, including bispecific antibody candidates and next-generation ADCs. With eight approved antibody medicines and a late-stage clinical portfolio expanding into oncology and immunology indications, the company is positioned to leverage its strengthened balance sheet to accelerate key registrational trials and pursue new collaborations.